VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 356 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2016. The put-call ratio across all filers is 1.00 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $1,000 | 0.0% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $1,000 | -94.1% | 20,000 | 0.0% | 0.00% | -90.0% |
| Q2 2017 | $17,000 | +142.9% | 20,000 | 0.0% | 0.01% | +150.0% |
| Q1 2017 | $7,000 | -81.1% | 20,000 | 0.0% | 0.00% | -87.5% |
| Q4 2016 | $37,000 | -66.4% | 20,000 | 0.0% | 0.03% | -44.8% |
| Q2 2016 | $110,000 | -54.4% | 20,000 | 0.0% | 0.06% | -70.9% |
| Q1 2016 | $241,000 | – | 20,000 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |